ASPRE
2017
Aspirin for Evidence-Based Preeclampsia Prevention trial
In 1,776 women with singleton pregnancies at high risk of preterm pre-eclampsia on first-trimester screening, aspirin 150 mg daily from 11–14 until 36 weeks reduced delivery with pre-eclampsia before 37 weeks compared with placebo.
Result
Efficacy: Delivery with pre-eclampsia before 37 weeks' gestationodds ratio 0.38 (95% CI 0.20-0.74) · P = 0.004
Below 1 favours aspirin 150 mg daily from 11–14 until 36 weeks, above 1 favours placebo.
- Absolute difference
- 2.7 points
- NNT
- 38
Absolute difference and NNT are derived from the event rates.
Also reported: No significant difference in neonatal adverse outcomes.
- Subtopic
- Pre-eclampsia prevention
- Design
- Double-blind, placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2025 Pregnancy
- Source
- Rolnik DL, Wright D, Poon LC, et al. N Engl J Med. 2017;377(7):613-622.doi 10.1056/NEJMoa1704559
Discussion & critique
The benefit is confined to preterm pre-eclampsia: term disease and hard perinatal outcomes were not significantly reduced, and the trial rests on few events. It established both the effective dose (150 mg, higher than the 75–81 mg used before) and the value of algorithm-based first-trimester screening.